Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9064643 | 0.79 | KMT2A (0.37) | MAPTATMALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL22153145 | 0.73 | RGS4 (0.46) | RGS4 | |
| SCHEMBL1398263 | 0.72 | MGLL (0.41) | CSNK2A1MAPTATMALDH1A1POLB | |
| SCHEMBL3470129 | 0.69 | RGS4 (0.53) | RGS4MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL8886547 | 0.68 | KMT2A (0.40) | MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4847030 | 0.68 | RGS4 (0.53) | RGS4MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14377608 | 0.67 | ALDH1A1 (0.41) | CSNK2A1MAPTATMALDH1A1POLB | |
| SCHEMBL6153732 | 0.67 | MAPK1 (0.58) | MAPTALDH1A1 | |
| SCHEMBL5798484 | 0.67 | MAPK1 (0.58) | MAPTALDH1A1 | |
| SCHEMBL30268729 | 0.67 | MAPK1 (0.58) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378419-B2 | 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | LES LABORATOIRES SERVIER (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1664055-B9 | 9-AMINO-PODOPHYLLOTOXIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SERVIER LAB (FR) | 2007-10-10 | — | — | EP | disclosed |
| EP-1664055-B1 | 9-AMINO-PODOPHYLLOTOXIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SERVIER LAB (FR) | 2006-12-13 | — | — | EP | disclosed |
| US-20060247246-A1 | 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247246-A1 | 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | SIK2, PTK2B, PLK2 | RGS4 3547/4885CSNK2A1 467/4885MAPT 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.